From Ganfyd

Jump to: navigation, search

Combination of the DOPA decarboxylase inhibitor benserazide and levodopa used for the treatment of Parkinsons disease. The ratio developed when levodopa was shown to be correct in most clinical practice by the end of the 1970s[1][2] and is regarded by most as therapeutically equivalent to co-careldopa[3] at equivalent levodopa dose.